Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022

Rhea-AI Summary

Vericel Corporation (NASDAQ:VCEL) will announce its second-quarter 2022 financial results on August 3, 2022, at 8:30 a.m. ET. The company specializes in advanced therapies for sports medicine and severe burn care, marketing MACI® and Epicel®, two cell therapy products. A conference call and webcast will follow the results announcement, accessible through their Investor Relations website. Vericel also holds the exclusive North American license for NexoBrid®, a product for severe thermal burns.

Positive

• Vericel is a leader in advanced therapies for sports medicine and severe burn care.
• The company markets two significant cell therapy products in the U.S.: MACI® and Epicel®.

Negative

• None.

CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2022 financial results on Wednesday, August 3, 2022. Vericel’s management will host a conference call and webcast at 8:30 a.m. (ET) to discuss the results and business highlights.

The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time in order to register and download the required audio software if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website. 

To participate by telephone, please register here to receive dial-in details and your personal passcode. A replay of the webcast will be available on the Vericel website until August 3, 2023.

About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI^® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel^® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid^®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit www.vcel.com.

Epicel^® and MACI^® are registered trademarks of Vericel Corporation. NexoBrid^® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved.

Investor Contacts:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

FAQ

When will Vericel report its Q2 2022 financial results?

Vericel will report its Q2 2022 financial results on August 3, 2022.

What time will Vericel's Q2 2022 conference call take place?

The conference call for Vericel's Q2 2022 results will occur at 8:30 a.m. ET.

Where can I access the Vericel conference call?

The conference call can be accessed through the Investor Relations section of Vericel's website.

What products does Vericel offer in the U.S.?

Vericel offers MACI® for cartilage repair and Epicel® for skin replacement in the U.S.

What is NexoBrid® and how is it related to Vericel?

NexoBrid® is a registration-stage biological orphan product for severe thermal burn debridement, and Vericel holds its exclusive North American commercial rights.